KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Work In Process (2016 - 2024)

Nektar Therapeutics (NKTR) has 12 years of Work In Process data on record, last reported at $10.6 million in Q2 2024.

  • For Q2 2024, Work In Process changed N/A year-over-year to $10.6 million; the TTM value through Jun 2024 reached $10.6 million, changed N/A, while the annual FY2023 figure was $12.9 million, 19.83% up from the prior year.
  • Work In Process reached $10.6 million in Q2 2024 per NKTR's latest filing, up from $10.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $12.9 million in Q4 2023 and bottomed at $10.0 million in Q1 2024.
  • Average Work In Process over 3 years is $11.3 million, with a median of $10.7 million recorded in 2022.
  • The widest YoY moves for Work In Process: up 19.83% in 2023, down 19.83% in 2023.
  • A 3-year view of Work In Process shows it stood at $10.7 million in 2022, then grew by 19.83% to $12.9 million in 2023, then fell by 17.78% to $10.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Work In Process were $10.6 million in Q2 2024, $10.0 million in Q1 2024, and $12.9 million in Q4 2023.